Michael Mauro, MD, hematologist, leader of the Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the side effects of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML).
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
![](https://s2.save4k.ru/pic/cDv4EuAZ1oE/maxresdefault.jpg)